Stoke Therapeutics to Present at Upcoming Investor Conferences in September
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, has announced its participation in two upcoming investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10 at 12:00 p.m. ET and the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17 at 11:30 a.m. ET.
These presentations offer investors an opportunity to gain insights into Stoke's progress and strategy. Live webcasts of both events will be available, with archived replays accessible on the company's investor relations website. This engagement with the investment community underscores Stoke's commitment to transparency and shareholder communication.
Stoke Therapeutics (Nasdaq: STOK), un'azienda biotecnologica focalizzata sulla medicina RNA per ripristinare l'espressione proteica, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno a settembre 2024. L'azienda presenterà al 26° Congresso Annuale di Investimento Globale H.C. Wainwright il 10 settembre alle 12:00 p.m. ET e al Congresso Globale sulla Salute di Cantor Fitzgerald 2024 il 17 settembre alle 11:30 a.m. ET.
Queste presentazioni offrono agli investitori un'opportunità per ottenere informazioni sui progressi e sulla strategia di Stoke. Webcast live di entrambi gli eventi saranno disponibili, con registrazioni archiviate accessibili sul sito web delle relazioni con gli investitori dell'azienda. Questo coinvolgimento con la comunità degli investitori sottolinea l'impegno di Stoke per la trasparenza e la comunicazione con gli azionisti.
Stoke Therapeutics (Nasdaq: STOK), una empresa de biotecnología centrada en la medicina de ARN para restaurar la expresión de proteínas, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024. La empresa presentará en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright el 10 de septiembre a las 12:00 p.m. ET y en la Conferencia Global de Salud de Cantor Fitzgerald 2024 el 17 de septiembre a las 11:30 a.m. ET.
Estas presentaciones ofrecen a los inversores la oportunidad de obtener información sobre los avances y la estrategia de Stoke. Se dispondrá de webcasts en vivo de ambos eventos, con grabaciones archivadas accesibles en el sitio web de relaciones con inversores de la empresa. Este compromiso con la comunidad inversora subraya el compromiso de Stoke con la transparencia y la comunicación con los accionistas.
Stoke Therapeutics (나스닥: STOK), 단백질 발현 복원을 위한 RNA 의학에 중점을 둔 생명공학 회사가 2024년 9월에 열리는 두 개의 투자자 콘퍼런스에 참여한다고 발표했습니다. 회사는 9월 10일 오후 12시(ET)에 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에서 발표할 예정이며, 9월 17일 오전 11시 30분(ET)에는 2024 Cantor Fitzgerald 글로벌 헬스케어 콘퍼런스에 참여할 것입니다.
이번 발표는 투자자들에게 Stoke의 진행 상황과 전략에 대한 통찰력을 제공할 기회를 제공합니다. 두 가지 이벤트 모두의 실시간 웹캐스트가 제공될 예정이며, 회사의 투자자 관계 웹사이트에서 아카이브된 재방송도 이용 가능합니다. 투자자 커뮤니티와의 이 engagement은 Stoke의 투명성과 주주 커뮤니케이션에 대한 의지를 강조합니다.
Stoke Therapeutics (Nasdaq: STOK), une entreprise de biotechnologie axée sur la médecine à base d'ARN pour restaurer l'expression des protéines, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. L'entreprise présentera lors de la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 10 septembre à 12h00 ET et lors de la Conférence Mondiale sur la Santé de Cantor Fitzgerald 2024 le 17 septembre à 11h30 ET.
Ces présentations offrent aux investisseurs l'occasion d'obtenir des informations sur les avancées et la stratégie de Stoke. Des webcasts en direct des deux événements seront disponibles, avec des rediffusions archivées accessibles sur le site web des relations investisseurs de l'entreprise. Cet engagement envers la communauté d'investissement souligne l'engagement de Stoke en matière de transparence et de communication avec les actionnaires.
Stoke Therapeutics (Nasdaq: STOK), ein biotechnologisches Unternehmen, das sich auf RNA-Medizin zur Wiederherstellung der Proteinexpression konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird am 10. September um 12:00 Uhr ET auf der 26. Jahrestagung für globale Investitionen von H.C. Wainwright präsentieren und am 17. September um 11:30 Uhr ET auf der 2024 Cantor Fitzgerald Global Healthcare Conference.
Diese Präsentationen bieten Investoren die Gelegenheit, Einblicke in die Fortschritte und Strategien von Stoke zu gewinnen. Live-Webcasts beider Veranstaltungen werden verfügbar sein, mit archivierten Wiederholungen, die auf der Investor-Relations-Website des Unternehmens zugänglich sind. Dieses Engagement mit der Investment-Community unterstreicht Stokes Engagement für Transparenz und Kommunikation mit den Aktionären.
- None.
- None.
H.C. Wainwright 26th Annual Global Investment Conference
Date: Tuesday, September 10, 2024
Time: 12:00 p.m. ET
2024 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024
Time: 11:30 a.m. ET
Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903002278/en/
Stoke Investor Contact:
Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485
Source: Stoke Therapeutics, Inc.
FAQ
When is Stoke Therapeutics (STOK) presenting at the H.C. Wainwright Global Investment Conference in 2024?
What time is Stoke Therapeutics (STOK) scheduled to present at the 2024 Cantor Fitzgerald Global Healthcare Conference?
How can investors access Stoke Therapeutics' (STOK) presentations at the September 2024 conferences?
What is the focus of Stoke Therapeutics' (STOK) biotechnology research?
